应对药物副作用有方法：氟替美维吸入粉雾剂(Trelegy Ellipta)常见不良反应缓解攻略

Flutimavir inhalation powder (TrelegyEllipta) is a triple compound inhalation preparation that can cause hearing loss, otitis media, fever, pneumonia, diarrhea and other side effects, and requires targeted treatment.

Side effects of flutimavir inhalation powder (Trelegy Ellipta)

1. Common adverse reactions in patients with chronic obstructive pulmonary disease

Among patients with chronic obstructive pulmonary disease, the most common adverse reactions are Common side effects include upper respiratory tract infection, pneumonia, bronchitis, oral candida infection, headache, back pain, joint pain, influenza, sinusitis, pharyngitis, rhinitis, abnormal taste, constipation, urinary tract infection, diarrhea, gastroenteritis, sore throat, cough, and hoarseness.

2. Common adverse reactions in patients with asthma

In patients with asthma, common side effects include pharyngitis/nasopharyngitis, upper respiratory tract infection, bronchitis, respiratory tract infection, sinusitis, urinary tract infection, rhinitis, influenza, headache and back pain.

3. Serious adverse reactions

Although uncommon, serious side effects may occur, such as pneumonia, immunosuppression, adrenal insufficiency, cardiovascular effects, osteoporosis, glaucoma, urinary retention, allergic reactions, etc., which require attention.

The pictures are from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Measurement and response measures to the side effects of Flutimavir Inhalation Powder Aerosol (Trelegy Ellipta)

1. Oral Candida infection

Rinse your mouth with water immediately after each inhalation and do not swallow. If infection occurs, local or systemic antifungal drugs should be used, and inhalation should be suspended if necessary.

2. Pneumonia risk

Pay attention to fever, worsening cough, increase or color change of sputum, shortness of breath, etc. Once symptoms of suspected pneumonia appear, seek medical attention immediately.

3. Adrenal insufficiency

Patients who switch to this drug after long-term use of oral corticosteroids should slowly reduce the dose of oral corticosteroids under the guidance of a doctor and carry a hormone warning card with them.

4. Cardiovascular and metabolic effects

Monitor heart rate, blood pressure, blood sugar and blood potassium levels. If palpitations, chest pain, tremor, etc. occur, seek medical attention in time.

5. Eye and urinary system problems

If you experience eye pain, blurred vision, color halo, etc., you should seek medical treatment immediately and be alert to glaucoma. If you have difficulty urinating or painful urination, you should stop taking the medicine and consult a doctor.

Pharmacokinetics of fluticasone inhalation powder (Trelegy Ellipta)

1. Absorption

(1) Fluticasone: peak plasma concentration is reached 0.5-1 hour after inhalation, and the absolute bioavailability is 15.2%.

(2) Umeclidinium bromide: reaches the peak 5-15 minutes after inhalation, and is mainly absorbed through the lungs.

(3) Vilanterol: reaches the peak 5-15 minutes after inhalation, and is almost completely absorbed by the lungs.

2. Distribution

The three components are widely distributed in the body and have high protein binding rates (fluticasone >99%, umeclidinium bromide about 89%, and vilanterol about 94%).

3. Metabolism and excretion

(1) Fluticasone: Mainly metabolized by liver CYP3A4, with a half-life of about 24 hours, and mainly excreted in feces.

(2) Umeclidinium bromide: mainly metabolized by CYP2D6, with an effective half-life of about 11 hours and excreted in feces and urine.

(3) Vilanterol: Mainly metabolized by CYP3A4, with an effective half-life of about 11 hours, and mainly excreted in urine.

4. Pharmacokinetics for special groups

(1) Patients with liver and kidney dysfunction: Patients with moderate to severe liver damage should use fluticasone with caution; patients with renal dysfunction generally do not need to adjust the dosage.

(2) Elderly people and racial differences: Age and race have no significant impact on pharmacokinetics, and there is no need to adjust the dose.